Add this topic to your myFT Digest for news straight to your inbox
Deal helps advance Bristol-Myers Squibb’s $90bn takeover of rival biotech giant Celgene
Offering is the largest bond issue of 2019 so far
Activist investor Starboard ends proxy fight after ISS and Glass Lewis support takeover
Wellington’s intervention in Bristol-Myers M&A battle could prove a turning point
Drugmaker has faced pushback from shareholders, including institutional investor Wellington
Activist Starboard joins Wellington Management joins fight against industry megamerger
Activist fund the latest to publicly criticise drugmaker’s planned $90bn takeover
Starboard’s demand for board seats raises questions over $90bn pharma deal
Bristol-Myers Squibb and Celgene $90bn merger ranks among most lucrative for banks
Deals including Bristol-Myers’ takeover of Celgene lift boutique adviser to top of league table
Bristol-Myers Squibb’s $90bn takeover sets stage for big pharma M&A in 2019
Cash-and-stock offer ranks as one of biggest ever pharma deals
The US needs a health secretary with the mettle to enact painful industry reforms
Failure to integrate an acquisition lay behind regulatory knock-back, says executive
Allergan and Celgene cut their securities investments as executives prepare to invest
Cancer treatment behind 63% of revenue could face competition from copycats in 2020
Regulatory blow for Murdoch, drugmakers’ M&A, Qualcomm’s fine, US airlines and GE
January M&A surge prompts questions over valuations
US tax overhaul spurs near-$30bn spree but some warn of bubble amid high valuations
Acquisition is second big purchase this year for the US biotech group
Deal for developer of cutting-edge cancer treatments would be its second big move of 2018
Deal worth up to $6.9bn depending on success of biotech start-up’s blood cancer drug
Disappointing prospects for new medicines has exposed lack of diversification
International Edition